patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent
COVID-19 or reduce the severity of the disease in high-risk populations. … In this Comment, we
summarize the neutralizing antibodies, including monoclonal antibodies (mAbs) and
nanobodies, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are
currently in preclinical development and in clinical trials, the antibodies’ potential mechanisms of …